The Benefits of Anticoagulation in Idiopathic Pulmonary Arterial Hypertension

Dec 14, 2023

490 likes | 494 Views

This article explores the potential benefits of anticoagulation therapy in idiopathic pulmonary arterial hypertension (IPAH), including its impact on prognosis and disease progression. It also discusses the possible risks associated with anticoagulation in IPAH patients.

Share Presentation

Embed Code

Link

anticoagulation
idiopathic pulmonary arterial hypertension
benefits
risks

jenaya

Download Presentation

The Benefits of Anticoagulation in Idiopathic Pulmonary Arterial Hypertension

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Pulmonary Arterial Hypertension Drug Pipeline Analysis

The Pulmonary Arterial Hypertension Market is Forecast to Show a High Growth Rate to 2015, but will Diminish in 2016

652 views • 4 slides

Pulmonary Arterial Hypertension: Review and Updates

Today

1.14k views • 42 slides

Clinical Suspicion of Pulmonary Arterial Hypertension

Clinical Suspicion of Pulmonary Arterial Hypertension. Echocardiogram. Right Ventricular Systolic Pressure (RVSP) ≤35 Investigate for other causes and/or review as appropriate. Right Ventricular Systolic Pressure (RVSP) > 35

282 views • 1 slides

Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis. It is an inflammation process involving all of the components of the alveolar wall The components of the alveolar wall include:. Alveolus. O 2. CO 2. Epithelial cells Endothelial cells Cellular and noncellular components of the interstitium

1.05k views • 8 slides

The Epidemiology of Idiopathic Pulmonary Fibrosis

The Epidemiology of Idiopathic Pulmonary Fibrosis. Vidya Navaratnam University of Nottingham. What is IPF?. Chronic, progressive, fibrotic lung disease of unknown aetiology More common in men Average age of presentation 71 years Median survival 3 years Lots of symptoms

454 views • 15 slides

Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis. OBJECTIVES. Know the definitions of ILD, IIP, and IPF. Understand the pathogenesis of IPF. Appreciate the clinical features. Realize how the diagnosis of IPF is made. Know current therapies.

799 views • 46 slides

Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis. Ganesh Raghu, MD, FACP, FCCP Professor of Medicine and Laboratory Medicine University of Washington Medical Center Chief, Chest Clinic Director: Interstitial Lung Disease and Lung Transplant Program. Classification of Idiopathic Interstitial Pneumonias.

1.58k views • 56 slides

Experimental Models of Pulmonary Arterial Hypertension

Experimental Models of Pulmonary Arterial Hypertension. Dr Figen Deveci F U , Department of Chest Disease s. PRESENTATION PLAN. 1. Definition of animal models of PAH 2. In generally, validity of animal models and differences from humans PAH.

1.02k views • 70 slides

Differentiate Pulmonary arterial hypertension from pulmonary venous congestion

Differentiate Pulmonary arterial hypertension from pulmonary venous congestion. Pulmonary Arterial Hypertension. Causes Primary/ Idiopathic Genetic Secondary Cardiac Pulmonary hypoxic vasoconstriction decreased area of the pulmonary vascular bed volume/pressure overload.

548 views • 9 slides

Diagnostic Evaluation of Pulmonary Arterial Hypertension: ACCP Guidelines

Diagnostic Evaluation of Pulmonary Arterial Hypertension: ACCP Guidelines. Lewis J. Rubin, MD, FCCP, FRCP University of California, San Diego. Lewis Rubin, MD, FCCP, Chair University of California, San Diego Steven H. Abman, MD University of Colorado Gregory S. Ahearn, MD

548 views • 42 slides

Arterial hypertension

Arterial hypertension. Arterial hypertension. New (1999) WHO-ISH Definitions and Classification of BP Levels. Category Systolic BP Diastolic BP (mm Hg) (mm Hg) Optimal BP <120 <80 Normal BP <130 <85 High-Normal 130-139 85-89 Grade 1 Hypertension (mild) 140-159 90-99

1.39k views • 55 slides

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension. Xiaosong Zhao, MD, PhD. Presbyterian Hospital of Dallas. January 3, 2006. Significance of Pulmonary arterial hypertension. Pulmonary arterial hypertension is the third cause of CHF. The median survival was 2.8 years with an estimated 5-year survival of 34%.

1.03k views • 64 slides

Pulmonary Hypertension

Pulmonary Hypertension. Kazemi.toba,M.D . Birjand University of Medical Sciences 24 th Ordibeheshte 1390. Outline. Introduction, definition Pathophysiology Diagnosis Laboratory Findings Idiopathic Pulmonary Arterial Hypertension Natural History Treatment. Introduction.

1.54k views • 58 slides

Pulmonary Arterial Hypertension – Pipeline Review, H1 2015

RnRMarketResearch.com adds “Pulmonary Arterial Hypertension – Pipeline Review, H1 2015” to its Store. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

169 views • 6 slides

The Features of Global Pulmonary Arterial Hypertension (PAH) Drugs Market

Market analysts forecast the global pulmonary arterial hypertension drugs market to grow at a CAGR of 3.2% during the period 2017-2021. The report covers the present scenario and the growth prospects of the global pulmonary arterial hypertension drugs market for 2017-2021. To calculate the market size, the report considers the MoA and the RoA.

106 views • 5 slides

Pulmonary Arterial Hypertension (PAH)

PAH Study-Healthy Solutions is offering a professional & expert team of doctors which serve the world-class cure and therapeutics of Pulmonary Arterial Hypertension (PAH) to the patient.

21 views • 1 slides

Pulmonary Arterial Hypertension

741 views • 64 slides

Arterial Hypertension

Arterial Hypertension. Presented By: Dr Emami. hypertension is the most common reason for office visits of non-pregnant adults to physicians in the United States and for use of prescription drugs.

1.11k views • 86 slides

Pulmonary Arterial Hypertension Market

According to DelveInsight, the market size of Pulmonary Arterial Hypertension in 7MM was found to be USD 4.6 Billion in 2017. Among the 7MM, the United States accounts for the largest market size of Pulmonary Arterial Hypertension, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. The total number of prevalent cases of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be 70,774, in the year 2017. The key players in the Pulmonary Arterial Hypertension market include United Therapeutics Corporation, Liquidia Technologies, Reata Pharmaceuticals, Altavant Sciences, Acceleron Pharma, PhaseBio Pharmaceuticals, Complexa, Arena Pharmaceuticals, Johnson & Johnson, GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc., Bayer AG, Pfizer, Bellerophon Pulse Technologies, and many others. For more information visit: https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pah-market#infographics #bloodpressure #bp #Pulmonaryarterialhypertension #hypertension

20 views • 1 slides

Pulmonary arterial hypertension - Herbal Treatment

Pulmonary arterial hypertension is also named as pulmonary hypertension. It is a life-threatening condition if left untreated for prolonged timewww.vaidjagjitsingh.com

28 views • 1 slides

Pulmonary Arterial Hypertension (PAH) Market

The global pulmonary arterial hypertension (PAH) market size was valued at USD 5.0 billion in 2015 and is anticipated to reach USD 8.7 billion by 2025.

40 views • 3 slides

Pulmonary Arterial Hypertension market

https://telegra.ph/What-is-Pulmonary-Arterial-Hypertensionc-and-its-market-size--share-01-14

37 views • 2 slides

More Related